Evolving role of stem cell transplantation in multiple myeloma

Clinical Lymphoma and Myeloma

Volumn 6, Issue 2, 2005, Pages 89-95

  Harousseau, Jean Luc ^a   Moreau, Philippe ^a  

^a HÔTEL DIEU   (France)

Author keywords

Autologous transplantation; Bortezomib; Combination therapy; Dose intensity; Lenalidomide; Thalidomide

Indexed keywords

BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER; BORTEZOMIB; DEXAMETHASONE; LENALIDOMIDE; MELPHALAN; PAMIDRONIC ACID; PREDNISONE; THALIDOMIDE; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; PYRAZINE DERIVATIVE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHROMOSOME DELETION 13; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; DOSE KIDNEY FUNCTION RELATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; EVENT FREE INTERVAL; FATIGUE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAINTENANCE THERAPY; MULTIPLE MYELOMA; PERIPHERAL NEUROPATHY; PROGNOSIS; PROTEIN BLOOD LEVEL; REDUCED INTENSITY CONDITIONING; RELAPSE; REVIEW; SURVIVAL; SURVIVAL RATE; TREATMENT RESPONSE; AUTOTRANSPLANTATION; CHROMOSOME 13; CHROMOSOME DELETION; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; GENETICS; METABOLISM; RANDOMIZED CONTROLLED TRIAL; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BETA 2-MICROGLOBULIN; BORONIC ACIDS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 13; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE MYELOMA; PYRAZINES; RANDOMIZED CONTROLLED TRIALS; STEM CELL TRANSPLANTATION; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 33644841895     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2005.n.034     Document Type: Review

References (57)

1. Attal M, Harousseau JL, Stoppa AM, et al. A randomized prospective trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335:91-97.
2. Child JA, Morgan GJ, Davies FC, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348:1875-1883.
3. Palumbo A, Bringhen S, Petrucci MT, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50-70: results of a randomized controlled trial. Blood 2004; 104:3052-3057.
4. 2 as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma. Final analysis of the IFM 95-02 randomized trial. Blood 2002; 99:731-735.
5. Badros A, Barlogie B, Siegel E, et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol 2001;114:600-607.
6. Badros A, Barlogie B, Siegel E, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114:822-829.
7. San Miguel J, Lahuerta JJ, Garcia-Sanz R, et al. Are myeloma patients with renal failure candidate for autologous stem cell transplantation. Hematol J 2000; 1:28-36.
8. Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998; 92:3131-3136
9. Blade J, Sureda A, Ribera JM, et al. High-dose therapy/ autotransplantation/ intensification versus continued conventional chemotherapy in multiple myeloma patients responding to initial chemotherapy. Definitive results from PETHEMA after a median follow-up of 66 months. Blood 2003; 102(suppl):42a-43a (Abstract #137).
10. 2 + TBI 12 Gy (MEL + TBI) versus standard therapy with VBMCP and no benefit from interferon (IFN) maintenance: final clinical results of Intergroup trial S9321 in the context of IFM90 and MRC VII trials. Blood 2004; 104(suppl):539a (Abstract #539).
11. Palumbo A, Bertola A, Musto P, et al. A prospective randomized trial of oral melphalan, prednisone, thalidomide (MPT) vs oral melphalan, prednisone (MP): an interim analysis. Blood 2003;102:148a (Abstract #509).
12. 2 for newly diagnosed myeloma patients ages 65-75 years: interim analysis of the IFM99-06 trial on 350 patients. Haematologica 2005; 90(suppl 1):56.
13. Anderson KC, Shaughnessy JD, Barlogie B, et al. Multiple Myeloma. American Society of Hematology Program Educational Book, 2002; 221-226.
14. Harousseau JL, Milpied N, Laporte JP, et al. Double intensive therapy in high-risk multiple myeloma. Blood 1992; 79:2827-2833.
15. Vesole D, Tricot G, Jagannath S, et al. Autotransplant in multiple myeloma: what have we learned? Blood 1996; 88:838-847.
16. Barlogie B, Jagannath S, Desikan KR, et al. Total therapy with tandem transplant for newly diagnosed multiple myeloma. Blood 1999; 93:55-65.
17. Desikan R, Barlogie B, Sawyer J, et al. Results of high dose therapy for 1000 patients with multiple myeloma: durable complete remission and superior survival in the absence of chromosome 13 abnormalities. Blood 2000; 95:4008-4010.
18. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem cell transplantation for multiple myeloma. N Engl J Med 2003; 349:2495-2502.
19. Sonneveld P, Van Der Holt B, Segeren CM, et al. Intensive versus double intensive therapy in untreated multiple myeloma. Updated analysis of the prospective phase III study Hovon 24-MM. Haematologica 2005; 90(suppl 1):37-38.
20. Cavo M, Zamagni E, Cellini C, et al. Single versus tandem autologous transplants in multiple myeloma: Italian experience. Haematologica 2005; 90(suppl 1):39-40.
21. Goldschmidt H. Single versus double high dose therapy in multiple myeloma: second analysis of the trial GMMG-HD2. Haematologica 2005; 90(suppl 1):38.
22. Fassas ABT, Spencer R, Sawyer J, et al. Both hypodiploidy and deletion of chromosome 13 independently confer post prognosis in multiple myeloma. Br J Haematol 2002; 118:1041-1047.
23. Shaughnessy J, Jacobson J, Sawyer J, et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy ensure long-term survival in myeloma treated with Total Therapy I: interpretation in the context of global gene expression. Blood 2003; 101:3849-3856.
24. Facon T, Avet-Loiseau H, Guillerm G, et al. Chromosome 13 abnormalities identified by FISH analysis and serum B2 microglobulin produce powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001; 97:1566-1571.
25. Moreau P, Hulin C, Garban E, et al. Final results of the IFM 9904 protocol: double transplant + anti-interleukin-6 monoclonal antibody in high-risk de novo multiple myeloma patients less than 65 years old. Haematologica 2005; 90(suppl 1):55-56.
26. Barlogie B, Tricot G, Shaughnessy J, et al. Results of total therapy 2 (TT2), a phase III randomized trial, to detemine the role of thalidomide (Thal) in the upfront management of multiple myeloma (MM). J Clin Oncol 2005; 23(suppl):560s (Abstract #6502).
27. Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20:4319-4323.
28. Weber D, Rankin K, Gavino M, et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21:16-19.
29. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with CC-5013 (lenalidomide; Revlimid™) plus dexamethasone (Rev/Dex) for newly diagnosed myeloma (MM). Blood 2004; 104(suppl):98a (Abstract #331).
30. Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005; 106:35-39.
31. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348:2609-2617.
32. Jagannath S, Barlogie B, Berenson J, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127:165-172.
33. Richardson P, Chanan-Khan A, Schlossman R, et al. Phase II trial of single agent bortezomib in patients with previously untreated multiple myeloma. Blood 2004; 104:100a (Abstract #336).
34. Jagannath S, Durie BGM, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129:776-783.
35. Harousseau JL, Attal M, Coiteux V, et al. Bortezomib (VELCADE®) plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: preliminary results of an IFM phase II study. J Clin Oncol 2005; 23:598s (Abstract #6653).
36. Oakervee HE, Popat R, Curry N, et al. PAD combination therapy (PS-341/ bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005; 129:755-762.
37. Barlogie B, Hollmig K, Zangari M, et al. Total therapy 3 for newly diagnosed myeloma, incorporating Velcade into remission induction with DT-PACE; early results regarding efficacy, PBSC mobilization and toxicities. Blood 2004; 104:156a (Abstract #538).
38. Alexanian R, Wang LM, Weber DM, et al. VTD (Velcade, thalidomide, dexamethasone) as primary treatment for newly diagnosed multiple myeloma. Blood 2004; 104:64a (Abstract #210).
39. Hollmig K, Stover J, Talamo G, et al. Addition of bortezomib to high-dose melphalan as an effective conditioning regimen with autologous stem cell support in multiple myeloma. Blood 2004; 104:266a (Abstract #929).
40. Bjorkstrand B, Svensson H, Goldschmidt H, et al. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the EBMT, Bone Marrow Transplant 2001; 27:511-515.
41. Cunningham D, Powles R, Malpas J, et al. A randomized trial of maintenance interferon following high-dose therapy in multiple myeloma: long-term follow-up results. Br J Haematol 1998; 102:195-202.
42. Attal M, Harousseau JL, Leyvraz S, et al. Maintenance treatment with thalidomide and pamidronate after autologous transplantation for myeloma: second analysis of a prospective randomized study of the Intergroupe Francophone du Myelome. Haematologica 2005; 90(suppl 1):17 (Abstract #PL4.01).
43. Richardson P, Schlossman R, Hideshima T, et al. A phase I trial of oral CC-5013 an immunomodulatory thalidomide derivative in patients with relapsed and refractory multiple myeloma. Blood 2002; 100:3063-3067.
44. Richardson P, Jagannath S, Schlossman R, et al. A multi-center randomized, phase II study to evaluate the efficacy and safety of two CC-5013 dose regimens, when used alone or in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. Blood 2002; 100(suppl):104a-105a (Abstract #386).
45. Lockhorst HM, Wu K, Verdonck LF, et al. The occurrence of graft-versus host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 2004; 103:4362-4364.
46. Lockhorst HM, Segeren CM, Verdonck LF, et al. Partially T-cell depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III Hovon 24 MM. J Clin Oncol 2003; 21:1728-1733.
47. Gahrton G, Svensson H, Cavo M, et al. Progress in allogeneic bone marrow and peripheral stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation. Br J Haematol 2001; 113:209-216.
48. Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood 2004; 103:20-32.
49. Giralt S, Aleman A, Anagnostopoulos A, et al. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant 2002; 30:367-373.
50. Einsele H, Shafer HJ, Hebart H, et al. Follow-up of patients with multiple myeloma undergoing allografts after reduced-intensity conditioning. Br J Haematol 2003; 121:411-418.
51. Badros A, Barlogie B, Spegel E, et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after non myeloablative conditioning. J Clin Oncol 2002; 20:1295-1303.
52. Kroger N, Sayer HG, Schwerdtfeger R, et al. Unrelated stem cell transplantation in multiple myeloma after reduced intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002; 100:3919-3924.
53. Harousseau JL, Shaughnessy J, Richardson P, eds. MultipLe Myeloma. American Society of Hematology Program Educational Book 2004; 244-248.
54. Maloney DG, Molina AJ, Sahebi F, et al. Allografting with non myeloablative conditioning following cytoreductive autograft for the treatment of patients with multiple myeloma. Blood 2003; 102:3447-3454.
55. Kroger N, Schwerdtfeger R, Kiehl M, et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002; 100:755-760.
56. Mohty M, Boiron JM, Damaj G, et al. Graft-versus-myeloma effect following antiothymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2004; 43:77-84.
57. Moreau P, Garban F, Facon T, et al. Preliminary results of IFM 9903 and 9904 protocols comparing autologous followed by miniallotransplantation and double autologous transplantation in high-risk de novo multiple myeloma. Blood 2003; 102(suppl):43a (Abstract #138).